← Eichor
Study identifier: NCT07423390 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

Condition: Peripheral Neuropathy Due to Chemotherapy · Peripheral Neuropathy, Chemotherapy-induced  ·  Sponsor: Qinghai Red Cross Hospital

PhasePhase 3
Planned participants326
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.

This description comes directly from the study's public registry record.

Talk to the study team

Jiuda Zhao, Dr  ·  869716230893  ·  jiudazhao@126.com

Always discuss trial participation with your own doctor first.

Locations (4)

Affiliated Hospital of Qinghai UniversityXining, Qinghai, ChinaNot Yet Recruiting
Qinghai Red Cross HospitalXining, Qinghai, ChinaRecruiting
Affiliated Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital)Jinan, Shandong, ChinaNot Yet Recruiting
Beijing Chaoyang Sanhuan Cancer HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07423390